Stockreport

Organovo's fatty liver disease drug meets main goal in mid-stage study [Reuters]

Organovo Holdings, Inc.  (ONVO) 
NASDAQ:AMEX Investor Relations: organovo.com/about/contact/investor-relations
PDF , opens new tab said on Monday its experimental drug to treat a type of fatty liver disease met the main goal in a mid-stage study, sending its shares up nearly 27% in [Read more]